Search Results - "Uemura, Hayato"

Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer by Oka, Miho, Xu, Liu, Suzuki, Toshihiro, Yoshikawa, Toshiaki, Sakamoto, Hiromi, Uemura, Hayato, Yoshizawa, Akiyasu C, Suzuki, Yutaka, Nakatsura, Tetsuya, Ishihama, Yasushi, Suzuki, Ayako, Seki, Masahide

“…Long-read sequencing of full-length cDNAs enables the detection of structures of aberrant splicing isoforms in cancer cells. These isoforms are occasionally…”
Get full text

Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model by Kashiwagi, Yoichiro, Aburaya, Shunsuke, Sugiyama, Naoyuki, Narukawa, Yuki, Sakamoto, Yuta, Takahashi, Masatomo, Uemura, Hayato, Yamashita, Rentaro, Tominaga, Shotaro, Hayashi, Satoko, Nozaki, Takenori, Yamada, Satoru, Izumi, Yoshihiro, Kashiwagi, Atsunori, Bamba, Takeshi, Ishihama, Yasushi, Murakami, Shinya

“…Periodontal infection induces systemic inflammation; therefore, aggravating diabetes. Orally administered periodontal pathogens may directly alter the gut…”
Get full text

Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19 by Uchida, Yoshihito, Uemura, Hayato, Yamaba, Shinpei, Hamada, Daisuke, Tarumoto, Norihito, Maesaki, Shigefumi, Mochida, Satoshi

“…Background COVID-19 has emerged as a threat to human health. Liver dysfunction has been reported to occur frequently in patients with COVID-19, although its…”
Get full text

NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir by Uemura, Hayato, Uchida, Yoshihito, Kouyama, Jun-ichi, Naiki, Kayoko, Tsuji, Shohei, Sugawara, Kayoko, Nakao, Masamitsu, Motoya, Daisuke, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Background This study sought to clarify the factors involved in virologic failure in patients with HCV receiving retreatment with glecaprevir/pibrentasvir…”
Get full text

Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria by Nakayama, Nobuaki, Uemura, Hayato, Uchida, Yoshihito, Imai, Yukinori, Tomiya, Tomoaki, Terai, Shuji, Yoshiji, Hitoshi, Genda, Takuya, Ido, Akio, Inoue, Kazuaki, Kato, Naoya, Sakaida, Isao, Shimizu, Masahito, Takikawa, Yasuhiro, Abe, Masanori, Abe, Ryuzo, Chayama, Kazuaki, Hasegawa, Kiyoshi, Inui, Ayano, Kasahara, Mureo, Ohira, Hiromasa, Tanaka, Atsushi, Takikawa, Hajime, Mochida, Satoshi

“…Background The significance of the 2018 Japanese diagnostic criteria for acute-on-chronic liver failure (ACLF) has not yet been evaluated. Methods A nationwide…”
Get full text

Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog by Uchida, Yoshihito, Nakao, Masamitsu, Yamada, Shunsuke, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun-Ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in…”
Get full text

Author Correction: Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model by Kashiwagi, Yoichiro, Aburaya, Shunsuke, Sugiyama, Naoyuki, Narukawa, Yuki, Sakamoto, Yuta, Takahashi, Masatomo, Uemura, Hayato, Yamashita, Rentaro, Tominaga, Shotaro, Hayashi, Satoko, Nozaki, Takenori, Yamada, Satoru, Izumi, Yoshihiro, Kashiwagi, Atsunori, Bamba, Takeshi, Ishihama, Yasushi, Murakami, Shinya

Get full text

A multicenter pilot survey to clarify the clinical features of patients with acute‐on‐chronic liver failure in Japan by Nakayama, Nobuaki, Uemura, Hayato, Uchida, Yoshihito, Tomiya, Tomoaki, Ido, Akio, Inoue, Kazuaki, Genda, Takuya, Takikawa, Yasuhiro, Sakaida, Isao, Terai, Shuji, Yokosuka, Osamu, Shimizu, Masahito, Takikawa, Hajime, Mochida, Satoshi

“…Aim To establish diagnostic criteria for acute‐on‐chronic liver failure (ACLF) in Japan, a multicenter pilot survey was carried out to examine the usefulness…”
Get full text

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus by Tsuji, Shohei, Uchida, Yoshihito, Uemura, Hayato, Kouyama, Jun‐Ichi, Naiki, Kayoko, Nakao, Masamitsu, Motoya, Daisuke, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Aim Factors responsible for impaired improvement of liver function despite sustained viral response after direct‐acting antiviral agents therapies in cirrhotic…”
Get full text

A case of genotype‐3b hepatitis C virus in which the whole genome was successfully analyzed using third‐generation nanopore sequencing by Uchida, Yoshihito, Kouyama, Jun‐ichi, Naiki, Kayoko, Uemura, Hayato, Tsuji, Shohei, Sugawara, Kayoko, Nakao, Masamitsu, Motoya, Daisuke, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…A 42‐year‐old Chinese man with chronic hepatitis C virus (HCV) infection visited our hospital for antiviral therapy. The subgenotype could not be determined…”
Get full text

Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation by Uchida, Yoshihito, Uemura, Hayato, Tsuji, Shohei, Yamada, Shunsuke, Kouyama, Jun‐ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakao, Masamitsu, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Background The Japanese guidelines for the treatment of cirrhosis suggest zinc supplementation to prevent hepatic encephalopathy in patients with cirrhosis and…”
Get full text

Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis by Uchida, Yoshihito, Inao, Mie, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun‐ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakao, Masamitsu, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Aim To optimize the therapeutic strategy for patients with decompensated cirrhosis manifesting hepatic ascites and/or edema, factors affecting the outcome of…”
Get full text

Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis by Uchida, Yoshihito, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun‐ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakao, Masamitsu, Inao, Mie, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Aim To optimize the therapeutic strategy for cirrhotic patients manifesting hepatic encephalopathy, factors affecting the outcome of patients receiving…”
Get full text

Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy by Uemura, Hayato, Uchida, Yoshihito, Kouyama, Jun‐ichi, Naiki, Kayoko, Yamaba, Shinpei, Fuchigami, Akira, Saito, Yoichi, Shiokawa, Keisuke, Fujii, Yohei, Uchiya, Hiroshi, Nakazawa, Manabu, Ando, Satsuki, Nakao, Masamitsu, Motoya, Daisuke, Sugawara, Kayoko, Inao, Mie, Imai, Yukinori, Nakayama, Nobuaki, Tomiya, Tomoaki, Mochida, Satoshi

“…Aim To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a…”
Get full text

Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos by Uchida, Yoshihito, Nakao, Masamitsu, Yamada, Shunsuke, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun-ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide…”
Get full text

Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleoside analog by Uchida, Yoshihito, Nakao, Masamitsu, Yamada, Shunsuke, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun-ichi, Naiki, Kayoko, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide…”
Get full text

Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate by Uchida, Yoshihito, Nakao, Masamitsu, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun‐ichi, Naiki, Kayoko, Motoya, Daisuke, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

“…The significance of switching of the nucleos(t)ide analog used to treat patients with hepatitis B virus (HBV) from entecavir (ETV) to tenofovir alafenamide…”
Get full text

Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA by Yamada, Shunsuke, Uchida, Yoshihito, Kouyama, Jun‐Ichi, Naiki, Kayoko, Tsuji, Shohei, Uemura, Hayato, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mizuno, Suguru, Mochida, Satoshi

“…Aim Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir…”
Get full text

Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir by Uchida, Yoshihito, Imai, Yukinori, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun‐ichi, Naiki, Kayoko, Ando, Satsuki, Sugawara, Kayoko, Nakao, Masamitsu, Nakayama, Nobuaki, Mizuno, Suguru, Tomiya, Tomoaki, Mochida, Satoshi

“…Aim To determine the outcomes concerning portal venous blood flow and portosystemic shunts in patients with decompensated cirrhosis due to hepatitis C virus…”
Get full text

Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate by Uchida, Yoshihito, Nakao, Masamitsu, Tsuji, Shohei, Uemura, Hayato, Kouyama, Jun‐ichi, Naiki, Kayoko, Motoya, Daisuke, Sugawara, Kayoko, Nakayama, Nobuaki, Imai, Yukinori, Tomiya, Tomoaki, Mochida, Satoshi

Get full text